Human Siglec-1/CD169 Affinity Purified Polyclonal Ab (25 UG)【科瑞奥博】

产品中心

当前位置：首页>产品中心

Human Siglec-1/CD169 Affinity Purified Polyclonal Ab (25 UG)

货号： AF5197-SP 基本售价： 1378.1 元规格： -

产品信息

概述
货号	AF5197-SP
别名	C19orf75; CD169; SIGLECL1 SIGLEC family like 1
全称	Sialic Acid Binding Ig-like Lectin 1
反应种属	Human
应用	Western Blot(1 µg/mL)
目标/特异性	Detects human Siglec‑1/CD169 in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Siglec-1 is observed and less than 1% cross-reactivity with recombinant human Siglec-2 is observed.
使用方法	Western Blot: 1 µg/mL Neutralization: Measured by its ability to neutralize Siglec‑1/CD169-mediated adhesion of human red blood cells. Kelm, S. et al. (1994) Current Biology 4:965. The Neutralization Dose (ND₅₀) is typically 1.5-7.5 µg/mL in the presence of 5 µg/mL Recombinant Human Siglec‑1/CD169 Fc Chimera.
来源	Polyclonal Sheep IgG
产品组分

性能
供应商	R&D Systems
Entrez Gene IDs	6614 (Human); 20612 (Mouse); 311426 (Rat)
应用文献
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1 Authors: JE Hammonds, N Beeman, L Ding, S Takushi, AC Francis, JJ Wang, GB Melikyan, P Spearman PLoS Pathog, 2017;13(1):e1006181. Species: Human Sample Type: Whole Cells Application: Flow Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer Authors: JQ Li, XJ Yu, YC Wang, LY Huang, CQ Liu, L Zheng, YJ Fang, J Xu J Transl Med, 2017;15(1):37. Species: Human Sample Type: Whole Tissue Application: IHC - Paraffin-embedded
纯化方式	Antigen Affinity-purified
免疫原	Mouse myeloma cell line NS0-derived recombinant human Siglec‑1/CD169 Ser20-Gln1641 Accession # Q9BZZ2
内毒素水平	<0.10 EU per 1 μg of the antibody by the LAL method.
生物活性	Human
标记	Unconjugated
溶解方法	Reconstitute at 0.2 mg/mL in sterile PBS.
背景	Siglecs are sialic acid specific I-type lectins that belong to the immunoglobulin superfamily. Structurally, they are transmembrane proteins with an N-terminal Ig-like V‑set domain followed by varying numbers of Ig-like C2-set domains (1, 2). Human Siglec-1, also known as sialoadhesin and CD169, is a 175‑185 kDa glycoprotein. It contains a 1622 amino acid (aa) extracellular domain (ECD) with one Ig-like V‑set domain and 16 Ig-like C2-set domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain (3). Within the ECD, human Siglec-1 shares approximately 70% aa sequence identity with mouse and rat Siglec-1. Alternate splicing generates a potentially soluble form of the ECD, and a second isoform with a substituted cytoplasmic domain. Siglec-1 expression is restricted to lymph node and splenic macrophages, plus some tissue macrophages (3). The adhesive function of Siglec-1 is supported by the N-terminal Ig-like domain which shows a selectivity for alpha 2,3‑linked sialic acid residues (3‑5). Siglec-1 binds a number of sialylated molecules including the mannose receptor, MGL1, MUC1, PSGL-1, and different glycoforms of CD43 (6‑9). Its binding capacity can be masked by endogenous sialylated molecules (10, 11). The sialylated and sulfated N-linked carbohydrates that modify Siglec-1 itself are required for ligand binding (6, 7). Siglec-1 is expressed on dendritic cells following rhinovirus exposure, and these DC promote T cell anergy (12). It is also induced on circulating monocytes during systemic sclerosis and HIV-1 infection (13‑15). Siglec-1 can trap HIV-1 particles for trans infection of permissive cells (14).
运输条件	Blue Ice
存放说明	4℃
参考文献	Varki, A. and T. Angata (2006) Glycobiology 16:1R. Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255. Hartnell, A. et al. (2001) Blood 97:288. Nath, D. et al. (1995) J. Biol. Chem. 270:26184. Crocker, P.R. et al. (1991) EMBO J. 10:1661. Martinez-Pomares, L. et al. (1999) J. Biol. Chem. 274:35211. Kumamoto, Y. et al. (2004) J. Biol. Chem. 279:49274. Nath, D. et al. (1999) Immunology 98:213. van den Berg, T.K. et al. (2001) J. Immunol. 166:3637. Nakamura, K. et al. (2002) Glycobiology 12:209. Barnes, Y.C. et al. (1999) Blood 93:1245. Kirchberger, S. et al. (2005) J. Immunol. 175:1145. York, M.R. et al. (2007) Arthritis Rheum. 56:1010. Rempel, H. et al. (2008) PloS ONE 3:e1967. van der Kuyl, A.C. et al. (2007) Plos ONE 2:e257.

参考图片

Detection of Human Siglec‑1 by Western Blot. Western blot shows lysates of SH‑SY5Y human neuroblastoma cell line and mouse lymph node tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human Siglec‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5197) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Siglec‑1 at approximately 180 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

Cell Adhesion Mediated by Siglec‑1/CD169 and Neutralization by Human Siglec‑1/CD169 Antibody.

Recombinant Human Siglec‑1/CD169 Fc Chimera (Catalog # 5197-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec‑1/CD169 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Human Siglec‑1/CD169 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5197). The ND₅₀ is typically 1.5-7.5 µg/mL.